Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ETBX-051 + ETBX-061 + ETBX-071 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ETBX-051 | ETBX051|ETBX 051 | ETBX-051 is a virally based vaccine that infects cells and induces expression of the brachyury protein protein, which may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against brachyury expressing tumor cells (PMID: 31594913). | ||
ETBX-061 | ETBX061|ETBX 061 | ETBX-061 is a virally based vaccine that infects cells and causes expression of the Muc1 protein, which may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against Muc1 expressing tumor cells (PMID: 31594913). | ||
ETBX-071 | ETBX 071|ETBX071|Adenoviral PSA Vaccine ETBX-071 | ETBX-071 is an engineered adenovirus vaccine that expresses human prostate specific antigen (PSA) in infected cells, which potentially activates cytotoxic T-lymphocytes against tumor cells expressing PSA (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03481816 | Phase I | ETBX-051 + ETBX-061 + ETBX-071 | Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines | Completed | USA | 0 |